Publications by authors named "Oluya M"
Background: Drug-resistant TB (DR-TB) remains a major public health threat. In 2022, Uzbekistan reported 2,117 cases of DR-TB, with 69% tested for fluoroquinolone resistance. Limited information is available on the prevalence of resistance to bedaquiline, linezolid, and fluoroquinolone, which are key components of the all-oral treatment regimen for rifampicin-resistant TB in Uzbekistan.
View Article and Find Full Text PDFBackground: Isoniazid (INH, H) resistance is the most common drug-resistant TB pattern, with treatment success rates lower than those in drug-susceptible TB. The WHO recommends a 6-month regimen of rifampicin (RIF, R), ethambutol (EMB, E), pyrazinamide (PZA, Z), and levofloxacin (Lfx) (6REZLfx) for INH-resistant, RIF-susceptible TB (HR-TB). Uzbekistan has a high burden of TB (62/100,000 population) and multidrug-resistant TB (12/100,000 population).
View Article and Find Full Text PDFArticle Synopsis
- Obesity is a growing global health issue, and while intragastric balloons are a minimally invasive treatment option, they can lead to serious complications like gastric outlet obstruction.
- A case of a 35-year-old woman who faced severe complications shortly after balloon placement highlights the need for careful patient selection and robust postoperative monitoring.
- The findings underscore the importance of personalized treatment plans and thorough assessments to prevent adverse outcomes, guiding future practices in obesity management.
Bedaquiline (BDQ) is widely used in the treatment of rifampicin-resistant TB (RR-TB). However, resistance to BDQ is now emerging. There are no standardised regimens for BDQ-resistant TB.
View Article and Find Full Text PDF